Anti-Rheumatic Drugs - North America

The Anti-Rheumatic Drugs market in North America is expected to witness impressive growth in the coming years.
According to projections, the revenue in this market is set to reach US$35.39bn by 2024.
Furthermore, it is anticipated to exhibit a steady annual growth rate (CAGR 2024-2029) of -1.22%, leading to a market volume of US$33.27bn by 2029.
When compared globally, it is noteworthy that United States will generate the highest revenue in this market, with an estimated value of US$34.70bn in 2024.
The North American region, particularly United States, holds significant potential in the Anti-Rheumatic Drugs market.
In North America, the demand for innovative anti-rheumatic drugs is on the rise, driven by a growing aging population and increased awareness about the benefits of early treatment.

Definition:
The market Anti-Rheumatic Drugs includes medication for the treatment of the inflammatory disease rheumatism. Due to the high prevalence of rheumatism and the large size of the market, this section of immune diseases is treated as a separate market. Both steroidal and non-steroidal anti-rheumatics are included. Disease-modifying rheumatic drugs (DMARDs), such as tumor necrosis factor inhibitors (a type of biologic DMARD), are particularly important in terms of commerciality.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: AbbVie, Johnson & Johnson, Pfizer, Amgen, Roche

Drugs to treat rheumatism
Steroidal (corticosteroids) and non-steroidal anti-rheumatics
Disease-modifying antirheumatic drugs (DMARDs)
Tumor necrosis factor (TNF) inhibitors

Drugs to treat other autoimmune diseases (such as multiple sclerosis or psoriasis)
Analgetics for general use (such as paracetamol)
Treatment of osteoarthritis

The demand for Anti-Rheumatic Drugs in North America has been on the rise in recent years.

Customer preferences: Patients suffering from rheumatoid arthritis and other related diseases in North America prefer Anti-Rheumatic Drugs due to their effectiveness in reducing inflammation and providing relief from pain. The increasing aging population and sedentary lifestyle have also contributed to the growing demand for these drugs.

Trends in the market: The Anti-Rheumatic Drugs market in North America has witnessed a shift towards biologic drugs due to their higher efficacy and lower side effects compared to traditional disease-modifying anti-rheumatic drugs (DMARDs). Additionally, there has been an increase in the use of combination therapies, where biologic drugs are used in combination with DMARDs, to achieve better outcomes.

Local special circumstances: The United States has the largest market share in North America due to the high prevalence of rheumatoid arthritis and other related diseases. The market in Canada is also growing due to the increasing awareness and availability of advanced treatments. However, the market in Mexico is relatively small due to the lack of access to advanced healthcare facilities and low awareness about rheumatic diseases.

Underlying macroeconomic factors: The North American market for Anti-Rheumatic Drugs is driven by factors such as increasing healthcare expenditure, favorable government initiatives, and technological advancements in drug development. The growing prevalence of rheumatoid arthritis and related diseases, especially among the aging population, is also contributing to the market growth. However, the high cost of biologic drugs and the availability of alternative therapies are some of the factors that may hinder market growth in the future.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.